🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06279247
Recruiting Observational

Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy

NCT06279247 · tracked via the Priya Life Science China tracker
Sponsor
Qilu Hospital of Shandong University
Phase
Observational
Started
2022-09-01
Last updated
2026-03-24

Condition(s) studied

Narcolepsy

Study summary

Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed.

At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy.

Eligibility

Sex
ALL
Min age
5 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria * All patients met the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3). Exclusion Criteria * primary hypersomnia or hypersomnia due to shift work, sleep deprivation and other sleep rhythm disturbances; * excessive sleep due to drug abuse; * suffering from Parkinson's disease, Alzheimer's disease and other nervous system diseases and mental diseases; * complicated with heart, lung, liver, kidney, blood endocrine system and other basic diseases, or acute chronic infection in a short period of time; * Use of sedatives, hypnotics, antidepressants, lithium and dopamine receptor antagonists for two weeks before examination; * patients who cannot cooperate with PSG and MSLT due to various factors.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Qilu Hospital of Shandong University Jinan Shandong Recruiting

More Qilu Hospital of Shandong University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06279247 on ClinicalTrials.gov ↗ ← All trials in China